Clinical Trial Update: Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of nivolumab in metastatic/adrenal cortex carcinoma (adrenocortical cancer) has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenal Cortex Carcinoma
• Adrenocortical Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Northwestern University | Conditions: Metastatic Carcinoma in the Adrenal Cortex, Recurrent Adrenal Cortex Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2019-05-01